Rein Therapeutics (RNTX) Earnings Date & Reports

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

RNTX is expected to report earnings to fall 10.00% to -9 cents per share on November 13

Rein Therapeutics RNTX Stock Earnings Reports

Q3'26

Est.

$-0.09

Q2'26

Beat

by $0.39

Q4'25

Missed

by $0.92

Q3'25

Missed

by $0.01

Q2'25

Missed

by $0.07

The last earnings report on August 14 showed earnings per share of -10 cents, beating the estimate of -49 cents. With 214.72K shares outstanding, the current market capitalization sits at 67.72M.

View a ticker or compare two or three

RNTX

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

View AI-Driven Trading for RNTX